NCT00688415 2019-09-25Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced CancerCelgenePhase 1 Completed33 enrolled
NCT01334177 2015-03-05TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and NeckUniversity of WashingtonPhase 1 Completed13 enrolled
NCT01294293 2014-12-25TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerGOG FoundationPhase 1 Completed20 enrolled